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Summary
Cobalamin (vitamin B12) deﬁciency occurs with several disorders, involving different organs and systems, including blood, bowel, nervous
system and eyes. Although the most important features are usually haematological ones, presence of neurological involvement, in the
absence of blood count alterations, has just been described in the literature. Here we report the case of a 48-year-old man, suffering from
coeliac disease for approximately 5 years, vegetarian, who was admitted to our department, referring dysaesthesia of the left lower limb,
decreased libido and erectile dysfunction. Vitamin B12 deﬁciency was proved, even in the absence of blood count alteration, and treated
with a vitamin supplement, resulting in complete remission.
BACKGROUND
A severe cobalamin (Cbl, vitamin B12) deﬁciency can occur
with several disorders, involving different organs and
systems, including blood, bowel, nervous system and eyes.1–
4 Although most of the patients have predominant haem-
atological manifestations, the presence of neurological
involvement, in the absence of blood count alterations, has
already been described. Moreover, a folic acid supplement
increases the risk of purely neurological presentation,
because it masks the haematological effects of vitamin B12
deﬁciency. First neurological onset is represented by numb-
ness and limb tingling, followed by progressive spastic
paresis and ataxia. Perception of deep touch, pressure and
vibration are generally reduced, Babinsky and Romberg signs
may be positive, and ﬁnally evoked potential tests are, some-
times, abnormal. Possible, although rare, are signs of cerebel-
lum dysfunction, peripheral neuropathy, sphincter
disturbances, optic atrophy and orthostatic hypotension.5–9
Histological demyelinating lesions can be pointed out, fol-
lowed by axonal degeneration and neuronal death, mainly
interesting posterior and lateral cords of the spinal cord.
Rare involvement of peripheral nerves, brain cortex and cere-
bellum may be demonstrated too. The lesions are visible as
multiple hyperintense areas in T2-MRI.10 11 Neurological
disorders completely regress after Cbl administration.12 13
In this report, we describe the case of a vegetarian man
aged 48, suffering from coeliac disease, under a gluten-free
diet, affected with hypovitaminosis B12-related multiple
sclerosis-like neurological manifestations, in the absence
of haematological disorders and/or other symptoms or
signs of organ distress. We excluded the hypothesis of a
lack of strict adherence to the gluten-free diet and of mal-
absorption due to ‘active’ coeliac disease, as antitransglu-
taminase and antiendomysial antibody assays were all
negative during the follow-up examinations, and duodenal
histology showed normal duodenal villi length (ie, Marsh
1 degree). Consequently, the primary cause of hypovitami-
nosis B12 and neurological symptoms was likely an intake
deﬁciency through food. Moreover, the intake of vegetable
foods, with high folate contents, may have led to the
absence of detectable haematological abnormalities.
CASE PRESENTATION
A 48-year-old man, who had suffered from coeliac disease
for approximately 5 years and was following a gluten-free
diet, was admitted to our department in February 2006,
referring dysaesthesia, starting from the left inguinal
region and spanning the entire ipsilateral lower limb, for
about 7 months, followed after 5 months by decreased
libido and erectile dysfunction.
In November 2000, due to a family history of coeliac
disease (brother and nephew) that was, however,
asymptomatic without symptoms/signs attributable to
malabsorption disorders, the patient underwent antitrans-
glutaminase IgG and IgA (positive) and antiendomysial
IgA (positive at a titre of 1 : 320) antibody assays and
human leucocyte antigen typing (DQ2 positive). Upper
gastrointestinal tract endoscopy showed ‘a small sliding
hiatal hernia; discoloration of the antral mucosa; normal
bulb and second portion of the duodenal mucosa’, while
duodenal biopsy found ‘marked villous atrophy and severe
inﬂammation of the lamina propria (Marsh 3c)’, thus con-
ﬁrming the coeliac disease diagnosis. The patient therefore
started a gluten-free diet and was periodically (yearly) fol-
lowed up as an outpatient. After 1 year of the gluten-free
diet, his general clinical condition was good, there were no
abnormalities on physical examination, and routine blood
chemistry tests were normal, except for slightly increased
transaminases (×1.5 the normal value), hyposideraemia
(12 mg/dl, male reference range 59.0–158.0 μg/dl) and
hypoferritinaemia (4 ng/ml, male reference range 30.0–
400.0 ng/ml). Serum antiendomysial IgA antibody assay
was negative due to strict adherence to the gluten-free diet.
In July 2005, he reported the onset of numbness,
described as a ‘pulse-vibration’ extending from the left
groin to the entire ipsilateral lower limb, followed in
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December of the same year by decreased libido and erectile
dysfunction. Physical examination was unrewarding, but
neurological examination showed tendon reﬂex asym-
metry, which was more evident on the right. Consequent
brain MRI with intravenous contrast showed ‘hyperin-
tense multiple periventricular and subcortical lesions’
(ﬁgure 1), and a full spine MRI with intravenous contrast
detected ‘hyperintensity at D9–D10 levels and disc protru-
sions at L3–L4 and L4–L5’. The above ﬁndings suggested a
diagnosis of ‘demyelinating leukoencephalopathy’.
In January 2006, the following were performed: cyto-
megalovirus (CMV) IgM and IgG antibody ELISA, CMV
IgG avidity and HIV ELISA evaluation, all with negative
results. Other autoantibody assays (antinuclear antibodies,
antimitochondrial antibodies, antismooth muscle anti-
bodies, liver/kidney microsomal antibodies, antiactin anti-
bodies, antiparietal cell antibodies and antiglomerular
basement membrane antibodies) were also negative, with
the exception of antinuclear antibodies, which were posi-
tive at a titre of 1 : 80.
In February 2006, the patient requested a consultation at
the specialist ‘Centre for Studies of Multiple Sclerosis’,
where routine blood tests were performed, all of which
were within the normal ranges, except for hypovitaminosis
B12 (51 pmol/l, reference range 156–672 pmol/l) and hyper-
cholesterolaemia (twofold the normal value). Tests were
also performed to evaluate serum folate (within the refer-
ence range), viral B and C hepatitis markers (negative),
lupus anticoagulant (absent), serum complement factors
C3 and C4 (within the reference range), free T3, free T4
and thyroid-stimulating hormone (within the reference
range) and homocysteinaemia (within the reference range).
Moreover, the patient underwent EEG, acoustic, visual and
somatosensory-evoked potentials and cerebrospinal ﬂuid
examination, which were all within normal limits. Since
the cerebrospinal ﬂuid data were negative, which did not
support the demyelinating leukoencephalopathy diagnosis,
the diagnosis was changed to ‘multifocal leukoencephalo-
pathy under clinical surveillance, in a patient with celiac
disease, hypovitaminosis B12 and dyslipidemia’. Low-dose
oral vitamin B12 treatment was recommended, as well as
follow-up brain and spinal cord MRI with contrast, and
after 6 months echo colour Doppler imaging of the carotid
vessels and a gastroenterological examination.
The same month the patient was readmitted to our out-
patient clinic for oesophag-gastroduodenoscopy with gastric
and duodenal biopsies (hiatal hernia, chronic atrophic gastri-
tis and Marsh 1 at D2 were observed). An accurate anam-
nesis of the patient’s dietary habits revealed that he had
been a vegetarian for 10 years. High-dose intramuscular
vitamin B1, B6 and B12 complex therapy was prescribed
three times a week. Moreover, he underwent antiparietal
cell and intrinsic factor antibody assay (negative), carotid
Doppler ultrasound (no pathological abnormalities) and
sacral somatosensory-evoked potentials test (abnormal due
to a pathological latency increase in P40 values).
Approximately 1 week after the administration of four
doses of intramuscular vitamins B1, B6 and B12 complex
the patient reported the disappearance of dysaesthesia,
recovery of libido and normalisation of erectile function.
Accordingly, we conﬁrmed the treatment and also added
folic acid (15 mg/day per os). Twenty days later, after 11
doses of intramuscular vitamins B1, B6 and B12 complex
had been administered, the therapy was changed, reducing
intramuscular vitamins B1, B6 and B12 complex to 1 phial/
week and folic acid to 15 mg/2 days a week. Serum
vitamin B12 was assayed after 45 days of treatment, showing
values >1200 pg/ml (normal range 174–878 pg/ml), as
well as serum folate, which was within the normal
reference range.
Figure 1 Brain MRI with intravenous contrast, showing multiple periventricular and subcortical hyperintense lesions.
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OUTCOME AND FOLLOW-UP
The patient is still being followed up as an outpatient in
our department due to the continued vitamin supplement
treatment to evaluate vitamin B12 and folate serological
values and investigate occasional reported dysaesthetic
disturbances. Brain and spinal cord MRI with intravenous
contrast performed after 12 months of therapy showed
‘improvement of hyperintense periventricular and subcor-
tical lesions and disc protrusions at L3–L4 and L4–L5’.
Antitransglutaminase and antiendomysial antibody assay
remain negative.
DISCUSSION
In this report we described the case of a vegetarian man,
aged 48, suffering from coeliac disease on a gluten-free
diet, with hypovitaminosis B12-related multiple sclerosis-
like neurological manifestations, in the absence of haem-
atological disorders and/or other symptoms or signs of
organ distress.
The correct approach to hypovitaminosis B12-related
neurological presentation includes accurate identiﬁcation of
the anatomical site of injury in order to reduce the aetiology
list. Dysaesthesia, decreased libido and erectile dysfunction,
the presenting symptoms in our report, may be the result of
damage to the parietal cortex, deep white matter, thalamus,
brain stem, spinal cord, spinal nerves or peripheral nerves.
Brain and spinal cord MRI with intravenous contrast identi-
ﬁed the lesions as ‘multifocal leukoencephalopathy’ or
‘white matter disease’. The latter is classiﬁed according to
histopathological criteria as demyelinating (characterised by
the loss of normal myelin, by an autoimmune/inﬂamma-
tory process ie, multiple sclerosis), dysmyelinating (usually
metabolic, centred on the unusual nature of myelin content,
ie, metachromatic leukodystrophy), hypomyelinating (marked
by a reduced production of myelin, ie, Pelizaeus-Merzbacher
disease) and myelinolytic or spongiform (associated with
myelin cystic degeneration, ie, central pontine myelinolysis).
Pathogenic considerations have also been added to the histo-
pathological classiﬁcation; thus at present it must be reclas-
siﬁed as ‘acquired’ or ‘hereditary’ (also known as
‘leukodystrophy’) white matter diseases. The main aetio-
logical factors responsible for the above-mentioned histo-
pathological abnormalities are reported in table 1.14–16
In our case, after excluding a primary hypothesis of
multiple sclerosis demyelinating multifocal leukoencepha-
lopathy based on the negative cerebrospinal ﬂuid examin-
ation and ﬁnding severe hypovitaminosis B12, a vitamin
deﬁciency was considered a likely origin for the neural
abnormalities. Although in many patients with vitamin
B12 or Cbl deﬁciency haematological manifestations are
predominant, they are variously associated with gastro-
enterological, neurological and psychiatric ones. The
present purely clinical neurological presentation, with no
detectable abnormalities in blood cell count, has already
been described in the literature. In this respect, it should
be pointed out how a folate supplement can mask the
haematological effects of vitamin B12 deﬁciency (ie, meg-
aloblastic anaemia), as was the case in our long-term vege-
tarian patient, increasing the risk of neural damage and
resulting neurological disorders.17 18
The ﬁrst neurological ﬁndings are numbness and tin-
gling in the limbs, followed by progressive spastic paresis
and ataxia. Perception of deep touch, pressure and vibra-
tion are generally reduced, Babinsky and Romberg signs
may be positive, and ﬁnally evoked potential tests are
sometimes abnormal. There are possible although rare
signs of cerebellum dysfunction, peripheral neuropathy,
sphincter disturbances, optic atrophy and orthostatic
hypotension.5–11
Daily minimum vitamin B12 requirement is 2.5 µg/day,
the only source being animal products. The body stores
3–5 mg, mainly in the liver; therefore clinical signs of
vitamin introduction deﬁciency or malabsorption only
appear after a period ranging from 2 to 5 years.1–4 19–21
The most important causes of vitamin B12 deﬁciency are
listed in table 2.22
To date, the pathogenesis of neurological disorders in
patients with Cbl deﬁciency has not been clariﬁed. Some
authors argue that neurological damage can be attributed,
at least in part, to deﬁciency in methionine synthesis,
with effects on myelin fatty acid synthesis. A new
hypothesis considers the abnormal Cbl deﬁciency-induced
synthesis of certain cytokines (ie, tumour necrosis factor
and interleukin-6), which has been proven to have a lytic
effect on myelin.19–23
Although Cbl deﬁciency can present primarily with a
degeneration of the posterior and lateral cords of the
spinal cord, thus causing symptoms/signs of peripheral
neuropathy, there is a possible although rare involvement
of the peripheral nerves and cerebral cortex and, more
rarely still, cerebellar cortex. In the early stages, the
Table 1 Pathophysiological classification of white matter
disease
I. Non-infectious inflammatory disorders
Multiple sclerosis and its variants
Acute disseminated encephalomyelitis
II. Infectious-inflammatory disorders
Congenital CMV infection
CMV subacute encephalitis
HIV subacute encephalitis
Subacute sclerosing panencephalitis
Progressive multifocal leukoencephalitis
Other infections
III. Toxic–metabolic disorders
Central pontine and extrapontine myelinolysis
Vitamin B12 deficiency
Folate deficiency
Marchiafava-Bignami disease
Malnutrition
Toxic encephalopathies (endogenous–exogenous)
IV. Hypoxic–ischaemic disorders
Cerebral autosomal dominant arteriopathy with subcortical infarcts and
Leukoencephalopathy
Periventricular leukomalacia
Polycystic leukoencephalopathy
Delayed hypoxic–ischaemic demyelination
Subcortical arteriosclerotic encephalopathy (Biswanger disease)
Normal ageing
Vasculitis (in the course of systemic lupus erythematosus, Bechet’s
disease, etc)
Radiations
V. Traumatic disorders
Shearing
Oedema
CMV, cytomegalovirus
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histological framework consists of demyelinating lesions
visible as multiple hyperintense areas on T2-MRI. These
are followed by axonal degeneration and ﬁnally by irre-
versible neuronal death. The earliest neurological manifes-
tations are numbness and tingling in the limbs, followed
by progressive spastic paresis and ataxia. Pulse, position
and kinetic sensitivity are generally reduced, Babinsky and
Romberg signs can be positive and evoked potentials are
often abnormal. Signs of cerebellar dysfunction, peripheral
neuropathy, sphincter disturbances, optic atrophy and
orthostatic hypotension are possible, although rare.5–11
In our case, the rapid disappearance of neurological
symptoms following treatment with a vitamin B12 sup-
plement conﬁrmed the hypothesis of ‘deﬁciency leukoen-
cephalopathy’. The mainstay of vitamin B12 deﬁciency
treatment is replacement, preferably via parenteral admin-
istration, as the deﬁciency is generally linked to a defect in
absorption. The dosage should correspond to the vitamin
B12 levels and clinical manifestations of the patient, the
initial parenteral treatment usually being 1000 µg of Cbl
for 8 weeks, followed by 1000 µg of Cbl per month for
life. The response is usually satisfactory, with the reso-
lution of haematological disorders and disappearance or
relief of neurological symptoms, although these symp-
toms are not always reversible.12 13 However, the patient
had a chronic atrophic gastritis, histologically proven. In
conjunction with vitamin B12 deﬁciency, this is at least
highly suspicious of pernicious anaemia. Negative
antibodies against parietal cells and intrinsic factor could
exclude the diagnosis, but sensitivities of 27% and 81%,
respectively, have been described.24–26 In addition, coeliac
disease is known to be associated with other autoimmune
diseases. Furthermore, the patient had been prescribed oral
vitamin B12 treatment (without success), but rapidly
improved after intramuscular supplementation—a typical
feature. Thus, we cannot entirely exclude the diagnosis of
pernicious anaemia, although negative speciﬁc autoanti-
bodies make this diagnosis less likely. Moreover, it is also
possible to hypothesise that patient chronic atrophic gas-
tritis might be related to a Helicobacter pylori infection,
unfortunately not investigated. In our patient we also
excluded the hypothesis of a lack of strict adherence to
the gluten-free diet, as antitransglutaminase and antien-
domysial antibody assays were all negative during the
follow-up examinations after 2004. Finally, duodenal hist-
ology was re-evaluated at the onset of the neurological
symptoms, as it has been demonstrated that villous
atrophy can persist several years after commencement of
a gluten-free diet, despite strict adherence to the diet.27
However, the patient showed normal duodenal villi length
(ie, Marsh 1 degree), thus excluding malabsorption due to
‘active’ coeliac disease. Consequently, the primary cause of
hypovitaminosis was likely an intake deﬁciency through
food.28 29 Moreover, the intake of vegetable foods, with
high folate contents, may have led to the absence of
detectable haematological abnormalities.18
Learning points
▸ Cobalamin (vitamin B12) deﬁciency occurs with several
disorders, involving different organs and systems,
including blood, bowel, nervous system and eyes.
▸ Although the most important features are usually
haematological ones, the presence of neurological
involvement (ie, multiple sclerosis-like neurological
manifestations), in the absence of blood count
alterations, has recently been described in the
literature.
▸ In our patient—examined for multiple sclerosis-like
neurological manifestations, vegetarian, with a
documented hypovitaminosis B12 and also affected
with coeliac disease—we excluded the hypothesis of a
lack of strict adherence to the gluten-free diet and of
malabsorption due to ‘active’ coeliac disease.
▸ Consequently, the primary cause of hypovitaminosis
B12 and neurological symptoms was likely an intake
through food deﬁciency. Moreover, the intake of
vegetable foods, with high folate contents, may have
led to the absence of detectable haematological
abnormalities.
▸ The patient was successfully treated with parenteral
administration of a vitamin B12 supplement.
Competing interests None.
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Table 2 Stages of cobalamin metabolism and corresponding
causes of cobalamin deficiency
Stages and actors in cobalamin
metabolism Causes of cobalamin deficiency
1. Intake solely through food • Strict vegetarianism (‘vegans’ or
patients who are sick in
institutions or in psychiatric
hospitals)
2. Digestion brings into play
• Gastric secretions
(hydrochloric acid and
pepsin)
• Haptocorrin
• Intrinsic factor
• Pancreatic and biliary
secretions
• Enterohepatic cycle
• Gastric achlorhydria
• Gastric secretion blocking drugs
• Gastrectomies (partial or total)
• Pernicious anaemia
• Intrinsic factor congenital
absence or malfunction (rare)
3. Absorption brings into play
• Cobalamin-intrinsic factor
complex
• Terminal ileum
• Cubilin and amnionless
(Cubam receptor)
• Calcium and energy
• Diseases of the terminal ileum
– Tropical sprue
– Non-tropical sprue
– Regional enteritis
– Granulomatous disorders
(rare)
– Malignancies
• Competition for cobalamin
– Parasitism (ie, tapeworms)
– Small intestinal bacterial
overgrowth
• Ileal or small bowel resections
• Imerslund-Grasbeck syndrome
(rare)
4. Transport by transcobalamins • Congenital deficiency in
transcobalamin II
5. Intracellular metabolism based on
various intracellular enzymes
• Nitrous oxide anaesthesia
• Congenital deficiency in various
intracellular enzymes
Dali-Youcef and Andres22 (modified).
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